Carisma Therapeutics, Inc.

NasdaqGM:CARM 주식 보고서

시가총액: US$35.4m

Carisma Therapeutics 미래 성장

Future 기준 확인 0/6

Carisma Therapeutics 의 수익과 수익은 각각 연간 48.7% 및 9.4% 감소할 것으로 예상됩니다. EPS는 연간 26.7% 만큼 성장할 것으로 예상됩니다.

주요 정보

-9.4%

수익 성장률

26.7%

EPS 성장률

Biotechs 수익 성장28.4%
매출 성장률-48.7%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트18 Nov 2024

최근 미래 성장 업데이트

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

May 12
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Recent updates

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

Sep 02
Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

May 12
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

Apr 19
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Mar 26
We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

Jan 21
Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Dec 07
The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Nov 12
Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

Oct 05
Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

수익 및 매출 성장 예측

NasdaqGM:CARM - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202610-71-65-642
12/31/202518-60-56-554
12/31/202421-54-63-633
9/30/202420-64-68-68N/A
6/30/202421-73-77-76N/A
3/31/202415-81-79-78N/A
12/31/202315-87-82-81N/A
9/30/202314-83-83-82N/A
6/30/202313-80-73-70N/A
3/31/202312-75-69-65N/A
12/31/202210-61-10-5N/A
9/30/20226-57-23N/A
6/30/20224-49-12N/A
3/31/20221-4347N/A
12/31/2021N/A-41-39-37N/A

애널리스트 미래 성장 예측

수입 대 저축률: CARM 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CARM 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CARM 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CARM 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -48.7% ).

고성장 수익: CARM 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -48.7% ).


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: CARM 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견